Candel Therapeutics (CADL) Operating Expenses (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Operating Expenses data on file, last reported at $15.8 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 93.49% year-over-year to $15.8 million; the trailing twelve-month figure through Dec 2025 stood at $48.3 million (up 44.63% YoY), and the FY2025 full-year result was $48.3 million, up 44.63% from the prior year.
• Operating Expenses rose to $15.8 million in Q4 2025, from $13.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $15.8 million in Q4 2025 to a low of $4.7 million in Q1 2021.
• A 5-year average of $9.0 million and a median of $8.8 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 189.93% in 2021 and retreated 21.1% in 2024, its largest moves.
• Tracing CADL's Operating Expenses over 5 years: stood at $7.8 million in 2021, then grew by 4.65% to $8.1 million in 2022, then grew by 26.88% to $10.3 million in 2023, then fell by 21.1% to $8.1 million in 2024, then surged by 93.49% to $15.8 million in 2025.
• Business Quant data shows CADL's Operating Expenses at $15.8 million in Q4 2025, $13.2 million in Q3 2025, and $11.2 million in Q2 2025.